Sanofi's Nexviazyme Hits All Endpoints in Phase 3 for Infantile Pompe Disease
SNY is trading near its 52-week low of $40.89 (6.2% above the low).
Summary
Sanofi announced positive Phase 3 results for its drug Nexviazyme in infantile-onset Pompe disease (IOPD), meeting all primary and secondary endpoints. This success paves the way for a US regulatory submission to expand the drug's label, which is currently approved for late-onset Pompe disease in the US and both forms in Europe. The positive trial outcome for this rare, severe condition adds to Sanofi's strong pipeline momentum, following several other recent positive clinical and regulatory updates. Data will be presented on July 8, 2026, with a US regulatory submission anticipated in the second half of 2026.
At the time of this announcement, SNY was trading at $43.43 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $103.1B. The 52-week trading range was $40.89 to $52.68. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.